Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) Short Interest Update

Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) saw a significant decline in short interest in May. As of May 15th, there was short interest totaling 2,735 shares, a decline of 86.4% from the April 30th total of 20,045 shares. Currently, 0.5% of the company’s stock are sold short. Based on an average daily trading volume, of 70,370 shares, the short-interest ratio is presently 0.0 days.

Sigyn Therapeutics Stock Down 7.9%

Shares of OTCMKTS:SIGY opened at $0.04 on Friday. The company has a market capitalization of $88,900.00 and a price-to-earnings ratio of -0.01. Sigyn Therapeutics has a 52 week low of $0.01 and a 52 week high of $5.00. The firm has a 50 day moving average of $0.04 and a 200 day moving average of $0.73.

About Sigyn Therapeutics

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.